|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to compare the efficiency of P300 and N200 potentials and reaction time (RT) with commonly used protein biomarkers measured in the cerebrospinal fluid (CSF), including amyloid β peptide (β1-42), total tau (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), tau protein phosphorylated at serine 199 (p-tau199), tau protein phosphorylated at threonine 231 (p-tau231), and visinin-like protein 1 (VILIP-1) in differential diagnosis of AD in mild cognitive impairment (MCI) and AD patients.
|
30207231 |
2018 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
P-tau and VILIP-1 were highly correlated (<i>r</i> = 0.639, <i>p</i> < 0.001) and strongly associated with Aβ pathology across clinical stages of AD, while YKL-40 was correlated with Aβ pathology in CN and AD groups.
|
30311914 |
2018 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize some of the pathological mechanisms implicated in the sporadic AD and highlight the data for several established and novel fluid biomarkers (including BACE1, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, α-synuclein, TDP-43, ferritin, VILIP-1, and NF-L) associated with each mechanism.
|
30488277 |
2018 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) from 51 AD subjects who participated in the randomized controlled trial Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX) was analyzed for the concentration of neurofilament light (NFL), neurogranin (Ng), visinin-like protein-1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40).
|
29067334 |
2017 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
These findings suggest a unique role for cerebrospinal fluid Vilip-1 as a biomarker of ERC neuron loss in AD.
|
26769253 |
2016 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
It has been revealed that NCS proteins, with special attention to visinin-like protein 1 (VILIP-1), might have a connection to the etiology of AD.
|
26402751 |
2015 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
CTD_human |
These findings provide an unbiased link between VSNL1 and molecular mechanisms of AD, including pathways implicated in synaptic pathology in AD.
|
25806004 |
2015 |
|
Alzheimer's Disease
|
0.490 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of Alzheimer's disease with psychotic symptoms.
|
22005930 |
2012 |
|
Alzheimer's Disease
|
0.490 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of Alzheimer's disease with psychotic symptoms.
|
22005930 |
2012 |
|
Alzheimer's Disease
|
0.490 |
AlteredExpression
|
disease |
BEFREE |
In addition to kalirin, the genes for voltage-gated Ca++ channel gamma subunit 3 and visinin-like protein 1 (a Ca++ sensor protein) were under-expressed, whereas inositol 1,4,5-triphosphate 3-kinase B was over-expressed in AD hippocampus.
|
17851188 |
2007 |
|
Alzheimer's Disease
|
0.490 |
PosttranslationalModification
|
disease |
LHGDN |
These results raise the possibility that the observed reduction in VILIP-1-expressing cells may indicate a selective vulnerability of these neurons and that the calcium sensor protein is involved in the pathophysiology of Alzheimer's disease.
|
11592857 |
2001 |
|
Alzheimer's Disease
|
0.490 |
Biomarker
|
disease |
BEFREE |
These results raise the possibility that the observed reduction in VILIP-1-expressing cells may indicate a selective vulnerability of these neurons and that the calcium sensor protein is involved in the pathophysiology of Alzheimer's disease.
|
11592857 |
2001 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
This raises the question, whether, similar to other potential schizophrenia susceptibility genes such as Disc1, PDE4B and Akt, VSNL1 may affect cAMP signaling and neurite outgrowth in neurons.
|
22832524 |
2011 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
BEFREE |
This raises the question, whether, similar to other potential schizophrenia susceptibility genes such as Disc1, PDE4B and Akt, VSNL1 may affect cAMP signaling and neurite outgrowth in neurons.
|
22832524 |
2011 |
|
Schizophrenia
|
0.330 |
AlteredExpression
|
disease |
LHGDN |
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.
|
19034380 |
2009 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
They include the calcium sensor gene visinin-like 1 (VSNL1) and the ionotropic AMPA glutamate receptor subunit (GRIA2), which were found to be down-regulated in the same cortical tissue from the schizophrenia group.
|
18184693 |
2008 |
|
Schizophrenia
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
They include the calcium sensor gene visinin-like 1 (VSNL1) and the ionotropic AMPA glutamate receptor subunit (GRIA2), which were found to be down-regulated in the same cortical tissue from the schizophrenia group.
|
18184693 |
2008 |
|
Alzheimer Disease, Late Onset
|
0.310 |
Biomarker
|
disease |
BEFREE |
Four less well-studied but promising "emerging" cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal-associated protein-25 (SNAP-25), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40).
|
30846386 |
2019 |
|
Alzheimer Disease, Late Onset
|
0.310 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |
|
Presenile dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |
|
Familial Alzheimer Disease (FAD)
|
0.300 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |
|
Alzheimer's Disease, Focal Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |
|
Alzheimer Disease, Early Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.
|
25806004 |
2015 |